NEW YORK (GenomeWeb News) – Autogenomics today said that it has received regulatory approval in Canada to market its Infiniti Pharmacogenomic testing system.

The Vista, Calif.-based firm received Health Canada Medical Device Class III approvals for the system along with two thrombolytic drug metabolism test kits, one for warfarin sensitivity and the other a 2C19 assay that indicates how a patient will metabolize commonly prescribed drugs.

The system and tests will be distributed in Canada by ESBE Scientific to labs providing clinical molecular testing services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.